Inventiva announces positive topline results from the : comp

Lanifibranor 800mg achieved the primary efficacy endpoint demonstrating a 44% reduction of hepatic fat measured by proton magnetic resonance spectroscopy...

Related Keywords

Daix , Bourgogne , France , Paris , France General , New York , United States , Ukraine , Russia , Michael Cooreman , Pascaline Clerc , Aude Lepreux , Department Of Medicine , University Of Florida , Exchange Commission On , Patricial Bank , Global External Affairs , Division Of Endocrinology , Brunswick Group , Nasdaq , Long Island City , Euronext Paris , Kenneth Cusi , Intra Hepatic Triglycerides , Chief Medical Officer , Principal Investigator , Analysis Set , Hepatic Insulin Resistance , Breakthrough Therapy , Fast Track , Nasdaq Global Market , Global External , Roquet Montegon , Private Securities Litigation Reform Act , New Drug Application , Universal Registration Document , Des March , Annual Report , Exchange Commission , Paris Stock Exchange Iva , Inventiva ,